Compare Amylx Pharmaceuticals Inc (AMLX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Consumer Staples Select Sector SPDR Fund trades at $84.3. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | XLP | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $90.00 |
52-Week Low | $7.64 | $75.61 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
XLP trades at $84.12, up 1.11% with a bearish technical signal despite neutral oscillators. The ETF maintains strong analyst support with 100% buy ratings and offers defensive exposure to consumer staples. Recent news highlights XLP's role as a safe haven during market uncertainty, with a 2.6% dividend yield providing income stability amid economic pressures.
The fund's defensive positioning and high dividend yield present opportunity during market volatility, though concentration in 36 holdings increases single-stock risk. Technical weakness suggests near-term pressure, but long-term fundamentals remain sound for investors seeking stable consumer staples exposure with income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
